ZA200707249B - Immunologically active compositions - Google Patents
Immunologically active compositionsInfo
- Publication number
- ZA200707249B ZA200707249B ZA200707249A ZA200707249A ZA200707249B ZA 200707249 B ZA200707249 B ZA 200707249B ZA 200707249 A ZA200707249 A ZA 200707249A ZA 200707249 A ZA200707249 A ZA 200707249A ZA 200707249 B ZA200707249 B ZA 200707249B
- Authority
- ZA
- South Africa
- Prior art keywords
- immunologically active
- active compositions
- compositions
- immunologically
- active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64816505P | 2005-01-28 | 2005-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200707249B true ZA200707249B (en) | 2010-08-25 |
Family
ID=36741156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200707249A ZA200707249B (en) | 2005-01-28 | 2006-01-30 | Immunologically active compositions |
Country Status (14)
Country | Link |
---|---|
US (2) | US9138467B2 (ja) |
EP (1) | EP1861117A4 (ja) |
JP (1) | JP5191740B2 (ja) |
KR (2) | KR101415864B1 (ja) |
CN (3) | CN105749264A (ja) |
AU (2) | AU2006207891C1 (ja) |
BR (1) | BRPI0607254A2 (ja) |
CA (1) | CA2606349C (ja) |
IL (1) | IL184907A (ja) |
MX (1) | MX2007009177A (ja) |
NZ (1) | NZ560543A (ja) |
RU (1) | RU2461390C2 (ja) |
WO (1) | WO2006081576A2 (ja) |
ZA (1) | ZA200707249B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010239463B2 (en) * | 2009-04-20 | 2016-12-08 | Galenbio, Inc. | Compositions for transfection of biomolecules into cells |
HUE059179T2 (hu) | 2012-09-10 | 2022-10-28 | Galenbio Inc | Vízimadárban Mycoplasma-fertõzés megelõzésére szolgáló oltóanyag |
PL3023777T3 (pl) * | 2013-09-09 | 2018-04-30 | Shimadzu Corporation | Sposób otrzymywania fragmentów peptydowych, zestaw do otrzymywania fragmentów peptydowych przeznaczony do stosowania w nim i sposób analizy |
CN107407666A (zh) * | 2015-03-09 | 2017-11-28 | 株式会社岛津制作所 | 使用质谱分析的单克隆抗体的检测方法 |
CN115932065A (zh) * | 2015-03-10 | 2023-04-07 | 株式会社岛津制作所 | 用于检测单克隆抗体的样品调制用试剂盒 |
US20230053449A1 (en) | 2018-10-31 | 2023-02-23 | Novartis Ag | Dc-sign antibody drug conjugates |
RU2743363C1 (ru) * | 2020-06-03 | 2021-02-17 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" | Способ тестирования иммунологической толерантности у животных |
RU2752967C1 (ru) * | 2021-02-10 | 2021-08-11 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр гематологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ гематологии" Минздрава России) | Способ индукции антигенассоциированного иммунного ответа |
WO2023010117A1 (en) * | 2021-07-30 | 2023-02-02 | William Marsh Rice University | Identification of pro- and anti-inflammatory lipids relating to immune response to medical implants |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5603960A (en) | 1993-05-25 | 1997-02-18 | O'hagan; Derek T. | Preparation of microparticles and method of immunization |
US5801063A (en) | 1995-05-09 | 1998-09-01 | Grandics; Peter | Device and process for the biospecific removal of heparin |
JPH11255664A (ja) | 1998-03-10 | 1999-09-21 | Ajinomoto Co Inc | 経口投与用免疫増強剤 |
US6521431B1 (en) | 1999-06-22 | 2003-02-18 | Access Pharmaceuticals, Inc. | Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments |
US20020061312A1 (en) | 2000-07-31 | 2002-05-23 | Ruslan Medzhitov | Innate immune system-directed vaccines |
US20030232055A1 (en) | 2000-07-31 | 2003-12-18 | Ruslan Medzhitov | Innate immune system-directed vaccines |
JP2008531580A (ja) | 2000-12-08 | 2008-08-14 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答修飾因子の標的化送達のための組成物および方法 |
US20030175287A1 (en) | 2001-01-03 | 2003-09-18 | Yale University | Innate immune system-directed vaccines |
RU2197248C2 (ru) * | 2001-03-20 | 2003-01-27 | Травкин Олег Викторович | Лекарственный препарат, обладающий иммуномоделирующим, иммунокоррегирующим, противопаразитарным, противосклеротическим, противовирусным, противобактериальным, противогрибковым, противовоспалительным и противоопухолевым действием, и способ его приготовления |
WO2002090520A2 (en) | 2001-05-09 | 2002-11-14 | Yale University | Toll/interleukin-1 receptor adaptor protein (tirap) |
CN100354297C (zh) | 2001-10-03 | 2007-12-12 | 希龙公司 | 辅助的脑膜炎球菌组合物 |
FR2832410B1 (fr) | 2001-11-19 | 2004-04-02 | Pasteur Institut | Antigene mycobacterien recombinant de type hemagglutinine de liaison a l'heparine methylee, procedes de preparation et compositions immunogenes comprenant un tel antigene |
AU2002361682A1 (en) * | 2001-12-14 | 2003-06-30 | Elizabeth Kopp | Innate immune system-directed vaccines |
MXPA01013257A (es) | 2001-12-18 | 2003-06-25 | Arturo Jimenez Bayardo | Suspension oftalmica de rofecoxib para el tratamiento de la inflamacion y el dolor ocular. |
AU2003235685A1 (en) | 2002-01-09 | 2003-07-30 | Ruslan M. Medzhitov | Rip2: a method of signaling in the innate and adaptive immune systems |
AU2003205071A1 (en) | 2002-01-09 | 2003-07-30 | Yale University | Irak-m is a negative regulator of toll-like receptor signaling |
EP1478327B1 (en) | 2002-02-22 | 2015-04-29 | Meda AB | Method of reducing and treating uvb-induced immunosuppression |
CN1440812A (zh) * | 2002-02-27 | 2003-09-10 | 上海中信国健药业有限公司 | 一种使用cd137结合激动剂增强免疫应答的方法 |
AU2003225054A1 (en) | 2002-04-19 | 2003-11-03 | Yale University | Toll-like receptor 11 and toll-like receptor 12 |
DK1545597T3 (da) | 2002-08-15 | 2011-01-31 | 3M Innovative Properties Co | Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons |
US7387271B2 (en) | 2002-12-30 | 2008-06-17 | 3M Innovative Properties Company | Immunostimulatory combinations |
WO2004080293A2 (en) | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Methods for diagnosing skin lesions |
US8426457B2 (en) | 2003-03-13 | 2013-04-23 | Medicis Pharmaceutical Corporation | Methods of improving skin quality |
US7923560B2 (en) | 2003-04-10 | 2011-04-12 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
RU2245142C1 (ru) * | 2003-07-14 | 2005-01-27 | Лимонов Виктор Львович | Иммуномодулятор |
EP2939693A1 (en) | 2003-08-14 | 2015-11-04 | 3M Innovative Properties Company | Lipid-modified immune response modifiers |
AU2004268616B2 (en) | 2003-08-25 | 2010-10-07 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
JP2007504145A (ja) | 2003-08-25 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫刺激性の組み合わせおよび治療 |
AU2004270201A1 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for CD5+ B cell lymphoma |
WO2005030133A2 (en) | 2003-09-22 | 2005-04-07 | Yale University | Treatment with agonists of toll-like receptors |
US20050096259A1 (en) | 2003-10-31 | 2005-05-05 | 3M Innovative Properties Company | Neutrophil activation by immune response modifier compounds |
FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
US20050158325A1 (en) | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Immunomodulatory combinations |
EP1699398A4 (en) | 2003-12-30 | 2007-10-17 | 3M Innovative Properties Co | IMPROVING THE IMMUNE RESPONSE |
WO2005077408A2 (en) | 2004-02-06 | 2005-08-25 | Vaxinnate Corporation | Compositions of pamps and listeria monocytogenes and methods of use |
MXPA06012451A (es) | 2004-04-28 | 2007-01-31 | 3M Innovative Properties Co | Composiciones y metodos para vacunacion por la mucosa. |
WO2006026470A2 (en) | 2004-08-27 | 2006-03-09 | 3M Innovative Properties Company | Hiv immunostimulatory compositions |
WO2006026394A2 (en) | 2004-08-27 | 2006-03-09 | 3M Innovative Properties Company | Method of eliciting an immune response against hiv |
WO2006029223A2 (en) | 2004-09-08 | 2006-03-16 | Children's Medical Center Corporation | Method for stimulating the immune response of newborns |
ES2434029T3 (es) | 2004-11-15 | 2013-12-13 | Novartis Vaccines And Diagnostics, Inc. | Composiciones inmunogénicas que contiene antígeno de antrax, micropartículas de polímero biodegradable, y adyuvante inmunológico que contiene polinucleótido |
CN102727885A (zh) | 2005-11-04 | 2012-10-17 | 诺华疫苗和诊断有限公司 | 包含颗粒佐剂和免疫增强剂组合的流感疫苗 |
ES2564241T3 (es) | 2005-12-02 | 2016-03-21 | Glaxosmithkline Biologicals Sa | Nanopartículas para su uso en composiciones inmunogénicas |
JP2009527572A (ja) | 2006-02-24 | 2009-07-30 | ノバルティス アーゲー | 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子 |
-
2006
- 2006-01-30 CA CA2606349A patent/CA2606349C/en not_active Expired - Fee Related
- 2006-01-30 KR KR20127013421A patent/KR101415864B1/ko active IP Right Grant
- 2006-01-30 BR BRPI0607254-2A patent/BRPI0607254A2/pt not_active Application Discontinuation
- 2006-01-30 CN CN201610091220.9A patent/CN105749264A/zh active Pending
- 2006-01-30 CN CN201710316568.8A patent/CN107261127A/zh active Pending
- 2006-01-30 US US11/814,355 patent/US9138467B2/en active Active
- 2006-01-30 EP EP06719946A patent/EP1861117A4/en not_active Ceased
- 2006-01-30 CN CNA2006800104428A patent/CN101370518A/zh active Pending
- 2006-01-30 MX MX2007009177A patent/MX2007009177A/es active IP Right Grant
- 2006-01-30 JP JP2007553350A patent/JP5191740B2/ja not_active Expired - Fee Related
- 2006-01-30 NZ NZ560543A patent/NZ560543A/en not_active IP Right Cessation
- 2006-01-30 AU AU2006207891A patent/AU2006207891C1/en not_active Ceased
- 2006-01-30 KR KR20077019701A patent/KR20070114727A/ko not_active Application Discontinuation
- 2006-01-30 ZA ZA200707249A patent/ZA200707249B/xx unknown
- 2006-01-30 WO PCT/US2006/003349 patent/WO2006081576A2/en active Application Filing
- 2006-01-30 RU RU2007131397/10A patent/RU2461390C2/ru active
-
2007
- 2007-07-29 IL IL184907A patent/IL184907A/en active IP Right Grant
-
2011
- 2011-02-14 AU AU2011200618A patent/AU2011200618B2/en not_active Ceased
-
2015
- 2015-08-24 US US14/833,454 patent/US9603917B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN107261127A (zh) | 2017-10-20 |
US20110117204A1 (en) | 2011-05-19 |
WO2006081576A2 (en) | 2006-08-03 |
KR101415864B1 (ko) | 2014-07-09 |
RU2461390C2 (ru) | 2012-09-20 |
NZ560543A (en) | 2012-01-12 |
AU2006207891B2 (en) | 2010-12-16 |
BRPI0607254A2 (pt) | 2009-08-25 |
CN105749264A (zh) | 2016-07-13 |
CA2606349A1 (en) | 2006-08-03 |
EP1861117A4 (en) | 2009-12-09 |
KR20070114727A (ko) | 2007-12-04 |
AU2006207891C1 (en) | 2011-09-01 |
IL184907A (en) | 2017-11-30 |
AU2006207891A2 (en) | 2009-07-16 |
CN101370518A (zh) | 2009-02-18 |
EP1861117A2 (en) | 2007-12-05 |
AU2011200618B2 (en) | 2012-12-13 |
US20150359870A1 (en) | 2015-12-17 |
AU2006207891A1 (en) | 2006-08-03 |
RU2007131397A (ru) | 2009-03-10 |
IL184907A0 (en) | 2007-12-03 |
CA2606349C (en) | 2019-03-05 |
US9138467B2 (en) | 2015-09-22 |
KR20120137346A (ko) | 2012-12-20 |
US9603917B2 (en) | 2017-03-28 |
AU2011200618A1 (en) | 2011-03-03 |
WO2006081576A3 (en) | 2008-10-16 |
JP2008529976A (ja) | 2008-08-07 |
JP5191740B2 (ja) | 2013-05-08 |
MX2007009177A (es) | 2008-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2424581B (en) | Formulations | |
IL191572A0 (en) | Pestcidal compositions | |
GB0503337D0 (en) | Compositions | |
IL186721A0 (en) | Bioenhanced compositions | |
IL188045A0 (en) | Immunogenic composition | |
EP1909584A4 (en) | PRENYLFLAVONOID FORMULATIONS | |
GB0501192D0 (en) | Stable prostaglandin-containing compositions | |
GB0526283D0 (en) | Compositions | |
GB0501365D0 (en) | Compositions | |
IL186093A0 (en) | Lignan-containing compositions | |
GB0505569D0 (en) | Formulations | |
GB0524128D0 (en) | Compositions | |
IL184907A0 (en) | Immunologically active compositions | |
ZA200709913B (en) | Bioenhanced compositions | |
GB0519871D0 (en) | Immunogenic agents | |
GB0526282D0 (en) | Compositions | |
GB2422150B (en) | PVA-containing compositions | |
GB0501364D0 (en) | Compositions | |
GB0506065D0 (en) | Compositions | |
GB0500917D0 (en) | Novel formulations | |
GB0519090D0 (en) | Novel formulations | |
GB0504106D0 (en) | Novel formulations | |
GB0500912D0 (en) | Novel formulations | |
GB0500913D0 (en) | Novel formulations | |
GB0522828D0 (en) | Novel formulations |